Sergio Cifuentes-Canaval, Medical Oncologist at Las Américas Auna Clinic, shared a post on X:
“Preventing HER2 degradation improves efficacy of trastuzumab deruxtecan (TDXd).
– Silencing of FBXL2 leads to increased HER2 expression on the plasma membrane and sensitizes HER2-0 TNBC cells to T-DXd treatment.
– Targeted inhibition of FBXL2 with ketoconazole (KCZ) encapsulated into LNPs prevents proteosome mediated degradation of HER2, resulting in increased HER2 expression, most notably on IHC 0 or HER2-low breast cancer cells.”
Title: Preventing HER2 degradation improves efficacy of trastuzumab deruxtecan
Author: Gail D. Lewis
Other articles about Trastuzumab Deruxtecan on OncoDaily.